Condition: Pemphigus Vulgaris · Pemphigus Foliaceus · Bullous Pemphigoid · Sponsor: University of Pennsylvania
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
This description comes directly from the study's public registry record.
Victoria P Werth, MD · 215-615-2940 · werth@pennmedicine.upenn.edu
Joyce Okawa, RN · 215-615-2960 · Joyce.Okawa@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Hospital of the University of Pennsylvania, Department of Dermatology | Philadelphia, Pennsylvania, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pennsylvania, Department of Dermatology | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02753777